Loading…

Immunome, Inc.IMNMCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops antibody-drug conjugates and biologics for cancer, discovered through a proprietary human antibody library.

Momentum laggard 19
Mkt cap
$1.98B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$27.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 18.4%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$16.78
1D-2.3%
1W-12.0%
1M-6.4%
3M-40.2%
6M-22.1%
YTD-21.9%
1Y-7.5%
ATR %7.6%
Beta1.56
52w lowhigh44.2% off high

What Immunome does

Develops antibody-drug conjugates and biologics for cancer, discovered through a proprietary human antibody library.

Has no product on sale and funds its trials with money from investors; revenue so far has been small payments for research work done for others. Varegacestat, acquired from Ayala Pharmaceuticals, targets desmoid tumours, a rare soft-tissue growth with few treatments, so the main events are late-stage trial results and regulatory decisions.

Products and services

  • Varegacestat (desmoid tumors)
  • ADC oncology pipeline

Customers

  • Oncologists/cancer centers (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Antibody-drug conjugate oncology

What could go right

  • Pivotal trial data readouts
  • Antibody library-driven pipeline growth

What could go wrong

  • Clinical trial failure risk
  • Small company financing and dilution risk

Moat: none (IP / patents, data). Proprietary human antibody library aids target discovery but company is clinical-stage with no approved products.

Headquarters: Exton, Pennsylvania, US · Founded: 2005 · Employees: 177

Named competitors

  • Mersana Therapeutics private or unlisted
  • Seagen (Pfizer) private or unlisted
  • ImmunoGen (AbbVie) private or unlisted
  • Sutro Biopharma STRO
  • ADC Therapeutics private or unlisted
  • Daiichi Sankyo 4568.T

Immunome at a glance

Size Immunome (IMNM) is a United States Health Care company (Biotechnology) with a market value of $1.98B, the 1776th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.78 on 18 Nov 2026.

Performance Over six months the shares fell 22.1%, against -3.8% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 19 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median -4.4%).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 97IMNM 73
Six months, rebased to 100: Immunome against the median of its 20 peers (local-currency closes).

Immunome financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$6.94M$9.04M$14.0M$0
Revenue growth—-23%-36%——
Gross profit-$3.75M$3.99M$6.94M$13.3M-$631,000
EBITDA-$287M-$211M-$151M-$109M-$36.3M
Net income-$283M-$212M-$293M-$107M-$36.9M
Free cash flow-$239M-$201M-$118M-$8.40M-$28.9M
Capital expenditure$9.67M$9.69M$7.17M$831,000$248,000
Total debt$11.4M$3.85M$4.83M$1.65M$62,000

Quarterly statements and history in the cockpit →

Immunome competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%AUPHTRVIMRVI688520REPLSEPNTRAXALMRVERAPVLACOAGZEALZBIOIMNM6-month return →1-month return →
Up and to the right = strong over both horizons. Immunome is the large dot.

Immunome competitors and peer comparison

Head to head with its named competitors (IMNM vs STRO vs 4568.T)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Immunome IMNM$1.98B-22%-100%n/an/an/a
Sutro Biopharma STROn/a-73%n/an/an/an/a
Daiichi Sankyo 4568.T$31.4B+8%+17%13%2.1×7.6%

How Immunome compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Immunome against its 20 peers (data as of 18 Nov 2026)
MeasureIMNMPeer medianRank in peer set
1-month return-6.4%-6.2%10th lowest of 20
6-month return-22.1%-3.8%5th lowest of 19
Distance from 52-week high-44.2%-34.1%7th lowest of 21
Revenue growth (TTM)-100.0%-4.4%2nd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a

Questions

Who are Immunome's main competitors?
Named competitors: Mersana Therapeutics (private or unlisted), Seagen (Pfizer) (private or unlisted), ImmunoGen (AbbVie) (private or unlisted), Sutro Biopharma (STRO), ADC Therapeutics (private or unlisted), Daiichi Sankyo (4568.T). The cockpit's measured peer set (industry) also includes Aurinia Pharmaceuticals (AUPH), Trevi Therapeutics (TRVI), Maravai Lifesciences (MRVI), Sinocelltech (688520.SS), Evopoint Biosciences (688837.SS), BioCryst Pharmaceuticals (BCRX).
How has Immunome stock performed?
Over six months to 18 Nov 2026 the shares returned -22.1% against -3.8% for the median peer; over one year -7.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.